% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Ippen:294558,
author = {F. Ippen$^*$ and T. Hielscher$^*$ and D. Friedel$^*$ and K.
Göbel$^*$ and D. Reuss$^*$ and C. Herold-Mende and S. Krieg
and A. von Deimling$^*$ and W. Wick$^*$ and F. Sahm$^*$ and
A. K. Suwala$^*$},
title = {{T}he prognostic impact of {CDKN}2{A}/{B} hemizygous
deletions in {IDH}-mutant glioma.},
journal = {Neuro-Oncology},
volume = {27},
number = {3},
issn = {1522-8517},
address = {Oxford},
publisher = {Oxford Univ. Press},
reportid = {DKFZ-2024-02333},
pages = {743-754},
year = {2025},
note = {#EA:B300#LA:B300# / 2025 Mar 7;27(3):743-754},
abstract = {Homozygous deletions of CDKN2A/B are known to predict poor
prognosis in gliomas, but the impact of hemizygous deletions
is less clear. This study aimed to evaluate the prognostic
significance of hemizygous CDKN2A/B deletions in IDH-mutant
low-grade astrocytomas and oligodendrogliomas.Tissue samples
diagnosed as astrocytoma, IDH-mutant and oligodendroglioma,
IDH-mutant, 1p/19q co-deleted CNS WHO grade 2 and 3 were
collected from the archives of the Institute of
Neuropathology in Heidelberg. DNA methylation analysis was
performed on formalin-fixed paraffin-embedded (FFPE)
samples. Evaluation of the CDKN2A/B locus was performed by
visual inspection of copy-number plots derived from
methylation-array data for each case. Hemizygous and
homozygous losses were assessed in relation to whole
chromosomal or larger segmental losses and gains in the
chromosomal profile. Survival probabilities were assessed
using the Kaplan-Meier method.A total of 334 low-grade
glioma cases were identified, including 173 astrocytomas and
161 oligodendrogliomas. Hemizygous deletions in CDKN2A/B
(37/173 in astrocytomas, 15/161 in oligodendrogliomas) did
not confer significantly worse survival outcomes compared to
CDKN2A/B wildtype cases in neither low grade astrocytoma
(log-rank p= 0.2556; HR 2.29, $95\%$ CI [0.76; 6.40], p=
0.135) nor oligodendroglioma (log-rank p= 0.2760; HR 0.17;
$95\%$ CI [0.01; 5.05]; p= 0.305), regardless of CNS WHO
grade, which was further demonstrated on a subgroup of
astrocytoma, IDH mutant CNS WHO 4 cases (log-rank p= 0.1680;
HR 4.55, $95\%$ CI [0.88; 24.51], p= 0.0689).Hemizygous
CDKN2A/B deletions do not significantly worsen OS or PFS in
IDH-mutant astrocytomas and oligodendrogliomas, CNS WHO
grade 2 and 3.},
keywords = {CDKN2A/B (Other) / IDH-mutant glioma (Other) / hemizygous
deletion (Other) / survival (Other)},
cin = {B300 / C060 / B320 / HD01},
ddc = {610},
cid = {I:(DE-He78)B300-20160331 / I:(DE-He78)C060-20160331 /
I:(DE-He78)B320-20160331 / I:(DE-He78)HD01-20160331},
pnm = {312 - Funktionelle und strukturelle Genomforschung
(POF4-312)},
pid = {G:(DE-HGF)POF4-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:39530475},
doi = {10.1093/neuonc/noae238},
url = {https://inrepo02.dkfz.de/record/294558},
}